Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.
We are developing an anticandidal vaccine using the recombinant N terminus of Als3p (rAls3p-N). We report that although more rAls3p-N was bound by aluminum hydroxide diluted in saline than by aluminum hydroxide diluted in phosphate-buffered saline (PBS), its immunogenicity and efficacy were superior in PBS. Thus, protein binding, by itself, may not predict the efficacy of some vaccines with aluminum adjuvants.
Lin
Lin
L
Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502, USA.
Ibrahim
Ashraf S
AS
Avanesian
Valentina
V
Edwards
John E
JE
Fu
Yue
Y
Baquir
Beverlie
B
Taub
Rebecca
R
Spellberg
Brad
B
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000737:chemistry; D000536:Aluminum Hydroxide / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D000818:Animals; D002021:Buffers; D002177:Candidiasis / Q000276:immunology / Q000517:prevention & control*; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005656:Fungal Proteins / Q000276:immunology; D005657:Fungal Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000276:immunology; D012965:Sodium Chloride; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D016896:Treatment Outcome
C113620:ALS3 protein, Candida albicans; D000276:Adjuvants, Immunologic; D002021:Buffers; D016207:Cytokines; D005656:Fungal Proteins; D005657:Fungal Vaccines; D011994:Recombinant Proteins; D012965:Sodium Chloride; D000536:Aluminum Hydroxide